Euroscreen S.A.

The TANGO beta-arrestin technology is a patented, universal GPCR testing technology proven to be an accurate method for screening potential drug candidates against know and orphan GPCR targets.

The agreement provides for Euroscreen's use of Life Technologies Corporation's TANGO beta-arrestin cell lines for drug discovery research services.  The parties have also agreed on terms that would allow for future development of new GPCR-based reagent assays.  Financial terms of this agreement were not disclosed.

"Our primary objective is to provide our existing customers with this powerful GPCR testing technology and to expand our offer of services.  We will also use this in selected research programs for deorphanization or drug discovery programs" stated Dr. Michel Detheux who heads Euroscreen FAST Business Unit for services and screening activities related to G protein coupled receptors (GPCRs).

Euroscreen FAST provides customers in academic, biotechnology and pharmaceutical research groups expertise in GPCR research that is recognized worldwide.  The business  unit provides scientific data and flexibility to support its customers' specific research needs.  Research services encompass functional High Throughput Screening, molecular pharmacology, functional profiling, functional antibodies development and testing and custom assay development - all based upon the largest catalog of functional assays targeting GPCRs.  Euroscreen FAST also provides research services for deorphanization of GPCRs by combining the largest collection of tissue extracts with different assay formats.  Euroscreen FAST's growing business capitalizes on over 15 years of validation and constant improvements in GPCR assay development at Euroscreen SA.

- ends -

About Euroscreen SA

Euroscreen is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs.  Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

Euroscreen pursues a dual business model strategy of combining its internal programs on high value targets (EUROSCREEN DRUG DISCOVERY) with its fully dedicated Business Unit (EUROSCREEN FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

Euroscreen has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Monogram Biosciences, Novartis and Pfizer. (www.euroscreen.com)

For further information, please contact:

Euroscreen S.A.
Michel Detheux, Ph. D
Director, Euroscreen FAST Business Unit
email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Al Gray, Ph. D
Director, Business Development
Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Tel: +32 71 348 500